Skip to main content
. 2016 Oct 7;16:547. doi: 10.1186/s12879-016-1903-6

Fig. 3.

Fig. 3

Propensity-score-weighted hazard ratios for composite CV event during as-treated follow-up period: Secondary comparisons. CI confidence interval, CV cardiovascular, DRV darunavir, HR hazard ratio, PI protease inhibitor